Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation

Steve N. Caritis; Shringi Sharma; Raman Venkataramanan; Dwight J. Rouse; Alan M. Peaceman; Anthony Sciscione; Catherine Y. Spong; Michael W. Varner; Fergal D. Malone; Jay D. Iams; Brian M. Mercer; John M. Thorp; Yoram Sorokin; Marshall Carpenter; Julie Lo; Susan Ramin; Margaret Harper

doi:10.1016/j.ajog.2011.03.028

Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation

Steve N. Caritis, Shringi Sharma, Raman Venkataramanan, Dwight J. Rouse, Alan M. Peaceman, Anthony Sciscione, Catherine Y. Spong, Michael W. Varner, Fergal D. Malone, Jay D. Iams, Brian M. Mercer, John M. Thorp, Yoram Sorokin, Marshall Carpenter, Julie Lo, Susan Ramin, Margaret Harper

Research output: Contribution to journal › Article › peer-review

37 Scopus citations

Abstract

Objective: The purpose of this study was to define the pharmacokinetic parameters of 17-hydroxyprogesterone caproate (17-OHPC) in multifetal gestation. Study Design: Blood was obtained at 24-28 weeks' gestation and at 3235 weeks gestation in 97 women with twin and 26 women with triplet gestation who were receiving 17-OHPC. Six of the women with twins had daily blood sampling for 7 days between 24 and 28 weeks' gestation, and pharmacokinetic parameters were estimated with the use of noncompartmental analysis. Modeling was applied to estimate the population parameters and to simulate various treatment scenarios. Results: The apparent half-life of 17-OHPC was 10 days. Body mass index significantly impacted 17-OHPC concentrations, but fetal number and parity did not. Apparent clearance was significantly greater in African American than in white women (P = .025). Conclusion: This is the first pharmacokinetic analysis of 17-OHPC in pregnant women. Determination of half-life, covariates that affect plasma 17-OHPC concentrations, and the modeling of drug behavior provide insights into this drug's pharmacologic properties during multifetal pregnancy.

Original language	English (US)
Pages (from-to)	40.e1-40.e8
Journal	American journal of obstetrics and gynecology
Volume	205
Issue number	1
DOIs	https://doi.org/10.1016/j.ajog.2011.03.028
State	Published - Jul 2011

Keywords

17-hydroxyprogesterone caproate
multifetal gestation
pharmacokinetics

ASJC Scopus subject areas

Obstetrics and Gynecology

Access to Document

10.1016/j.ajog.2011.03.028

Cite this

Caritis, S. N., Sharma, S., Venkataramanan, R., Rouse, D. J., Peaceman, A. M., Sciscione, A., Spong, C. Y., Varner, M. W., Malone, F. D., Iams, J. D., Mercer, B. M., Thorp, J. M., Sorokin, Y., Carpenter, M., Lo, J., Ramin, S., & Harper, M. (2011). Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation. American journal of obstetrics and gynecology, 205(1), 40.e1-40.e8. https://doi.org/10.1016/j.ajog.2011.03.028

Caritis, SN, Sharma, S, Venkataramanan, R, Rouse, DJ, Peaceman, AM, Sciscione, A, Spong, CY, Varner, MW, Malone, FD, Iams, JD, Mercer, BM, Thorp, JM, Sorokin, Y, Carpenter, M, Lo, J, Ramin, S & Harper, M 2011, 'Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation', American journal of obstetrics and gynecology, vol. 205, no. 1, pp. 40.e1-40.e8. https://doi.org/10.1016/j.ajog.2011.03.028

@article{380b492c016546c88aa8c4365e281b15,

title = "Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation",

abstract = "Objective: The purpose of this study was to define the pharmacokinetic parameters of 17-hydroxyprogesterone caproate (17-OHPC) in multifetal gestation. Study Design: Blood was obtained at 24-28 weeks' gestation and at 3235 weeks gestation in 97 women with twin and 26 women with triplet gestation who were receiving 17-OHPC. Six of the women with twins had daily blood sampling for 7 days between 24 and 28 weeks' gestation, and pharmacokinetic parameters were estimated with the use of noncompartmental analysis. Modeling was applied to estimate the population parameters and to simulate various treatment scenarios. Results: The apparent half-life of 17-OHPC was 10 days. Body mass index significantly impacted 17-OHPC concentrations, but fetal number and parity did not. Apparent clearance was significantly greater in African American than in white women (P = .025). Conclusion: This is the first pharmacokinetic analysis of 17-OHPC in pregnant women. Determination of half-life, covariates that affect plasma 17-OHPC concentrations, and the modeling of drug behavior provide insights into this drug's pharmacologic properties during multifetal pregnancy.",

keywords = "17-hydroxyprogesterone caproate, multifetal gestation, pharmacokinetics",

author = "Caritis, {Steve N.} and Shringi Sharma and Raman Venkataramanan and Rouse, {Dwight J.} and Peaceman, {Alan M.} and Anthony Sciscione and Spong, {Catherine Y.} and Varner, {Michael W.} and Malone, {Fergal D.} and Iams, {Jay D.} and Mercer, {Brian M.} and Thorp, {John M.} and Yoram Sorokin and Marshall Carpenter and Julie Lo and Susan Ramin and Margaret Harper",

note = "Funding Information: Supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development ( HD27869 , HD21410 , HD40512 , HD34136 , HD34208 , HD40485 , HD27915 , HD40544 , HD40560 , HD27917 , HD40500 , HD34116 , HD40545 , HD27860 , HD36801 ) and does not necessarily represent the official views of the National Institute of Child Health and Human Development or the National Institutes of Health. ",

year = "2011",

month = jul,

doi = "10.1016/j.ajog.2011.03.028",

language = "English (US)",

volume = "205",

pages = "40.e1--40.e8",

journal = "American journal of obstetrics and gynecology",

issn = "0002-9378",

publisher = "Mosby Inc.",

number = "1",

}

TY - JOUR

T1 - Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation

AU - Caritis, Steve N.

AU - Sharma, Shringi

AU - Venkataramanan, Raman

AU - Rouse, Dwight J.

AU - Peaceman, Alan M.

AU - Sciscione, Anthony

AU - Spong, Catherine Y.

AU - Varner, Michael W.

AU - Malone, Fergal D.

AU - Iams, Jay D.

AU - Mercer, Brian M.

AU - Thorp, John M.

AU - Sorokin, Yoram

AU - Carpenter, Marshall

AU - Lo, Julie

AU - Ramin, Susan

AU - Harper, Margaret

N1 - Funding Information: Supported by grants from the Eunice Kennedy Shriver National Institute of Child Health and Human Development ( HD27869 , HD21410 , HD40512 , HD34136 , HD34208 , HD40485 , HD27915 , HD40544 , HD40560 , HD27917 , HD40500 , HD34116 , HD40545 , HD27860 , HD36801 ) and does not necessarily represent the official views of the National Institute of Child Health and Human Development or the National Institutes of Health.

PY - 2011/7

Y1 - 2011/7

N2 - Objective: The purpose of this study was to define the pharmacokinetic parameters of 17-hydroxyprogesterone caproate (17-OHPC) in multifetal gestation. Study Design: Blood was obtained at 24-28 weeks' gestation and at 3235 weeks gestation in 97 women with twin and 26 women with triplet gestation who were receiving 17-OHPC. Six of the women with twins had daily blood sampling for 7 days between 24 and 28 weeks' gestation, and pharmacokinetic parameters were estimated with the use of noncompartmental analysis. Modeling was applied to estimate the population parameters and to simulate various treatment scenarios. Results: The apparent half-life of 17-OHPC was 10 days. Body mass index significantly impacted 17-OHPC concentrations, but fetal number and parity did not. Apparent clearance was significantly greater in African American than in white women (P = .025). Conclusion: This is the first pharmacokinetic analysis of 17-OHPC in pregnant women. Determination of half-life, covariates that affect plasma 17-OHPC concentrations, and the modeling of drug behavior provide insights into this drug's pharmacologic properties during multifetal pregnancy.

AB - Objective: The purpose of this study was to define the pharmacokinetic parameters of 17-hydroxyprogesterone caproate (17-OHPC) in multifetal gestation. Study Design: Blood was obtained at 24-28 weeks' gestation and at 3235 weeks gestation in 97 women with twin and 26 women with triplet gestation who were receiving 17-OHPC. Six of the women with twins had daily blood sampling for 7 days between 24 and 28 weeks' gestation, and pharmacokinetic parameters were estimated with the use of noncompartmental analysis. Modeling was applied to estimate the population parameters and to simulate various treatment scenarios. Results: The apparent half-life of 17-OHPC was 10 days. Body mass index significantly impacted 17-OHPC concentrations, but fetal number and parity did not. Apparent clearance was significantly greater in African American than in white women (P = .025). Conclusion: This is the first pharmacokinetic analysis of 17-OHPC in pregnant women. Determination of half-life, covariates that affect plasma 17-OHPC concentrations, and the modeling of drug behavior provide insights into this drug's pharmacologic properties during multifetal pregnancy.

KW - 17-hydroxyprogesterone caproate

KW - multifetal gestation

KW - pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=80052523645&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052523645&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2011.03.028

DO - 10.1016/j.ajog.2011.03.028

M3 - Article

C2 - 21620357

AN - SCOPUS:80052523645

SN - 0002-9378

VL - 205

SP - 40.e1-40.e8

JO - American journal of obstetrics and gynecology

JF - American journal of obstetrics and gynecology

IS - 1

ER -

Pharmacokinetics of 17-hydroxyprogesterone caproate in multifetal gestation

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this